Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses

Area of Science:

• Immunology
• Neuroimmunology
• Chronobiology

Background:

• Multiple sclerosis (MS) is a chronic immune-mediated disorder affecting the central nervous system.
• Glucocorticoids are a primary treatment for MS relapses, but their optimal administration timing is not fully understood.
• Chronobiology, the study of biological rhythms, suggests that treatment timing can influence therapeutic efficacy and side effects.

Purpose of the Study:

• To compare the effects of daytime versus nighttime intravenous glucocorticoid administration on immune biomarkers during MS relapses.
• To investigate potential chronobiological influences on glucocorticoid therapy in MS patients.

Main Methods:

• A study involving 35 patients with multiple sclerosis experiencing relapses.
• Measurement of serum levels for C-reactive protein (CRP), tumor necrosis factor-alpha (TNFalpha), erythrocyte sedimentation rate (ESR), matrix metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2.
• Analysis of biomarkers at baseline and 7 days post-initiation of intravenous glucocorticoid treatment, comparing daytime versus nighttime administration.

Main Results:

• Serum MMP-9 protein levels were significantly lower following nighttime glucocorticoid treatment compared to daytime treatment.
• Both daytime and nighttime treatment regimens resulted in comparable reductions in ESR, CRP, and TNFalpha levels.
• No significant differences were observed for MMP-2, TIMP-1, and TIMP-2 levels between the two treatment groups.

Conclusions:

• Nighttime administration of intravenous glucocorticoids may offer a differential effect on MMP-9 levels in MS relapses.
• These findings suggest that the timing of glucocorticoid administration could be a relevant factor in managing MS relapses and potentially other immune disorders.
• Further research is warranted to fully characterize the role of chronobiology in glucocorticoid therapeutics for immune-mediated diseases.